- Home
- PDS vs OCS Comparison
PDS vs OCS Comparison
Compare PDS & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDS
- OCS
- Stock Information
- Founded
- PDS 1951
- OCS 2003
- Country
- PDS Canada
- OCS Switzerland
- Employees
- PDS N/A
- OCS N/A
- Industry
- PDS
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- PDS
- OCS Health Care
- Exchange
- PDS Nasdaq
- OCS Nasdaq
- Market Cap
- PDS 872.2M
- OCS 904.3M
- IPO Year
- PDS N/A
- OCS N/A
- Fundamental
- Price
- PDS $46.57
- OCS $19.03
- Analyst Decision
- PDS Buy
- OCS Strong Buy
- Analyst Count
- PDS 1
- OCS 4
- Target Price
- PDS $95.00
- OCS $29.50
- AVG Volume (30 Days)
- PDS 125.0K
- OCS 42.6K
- Earning Date
- PDS 04-23-2025
- OCS 03-11-2025
- Dividend Yield
- PDS N/A
- OCS N/A
- EPS Growth
- PDS N/A
- OCS N/A
- EPS
- PDS 5.43
- OCS N/A
- Revenue
- PDS $1,322,126,157.00
- OCS $757,024.00
- Revenue This Year
- PDS $4.87
- OCS $927.26
- Revenue Next Year
- PDS $2.91
- OCS $292.79
- P/E Ratio
- PDS $8.55
- OCS N/A
- Revenue Growth
- PDS N/A
- OCS N/A
- 52 Week Low
- PDS $43.00
- OCS $10.55
- 52 Week High
- PDS $79.07
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- PDS 44.38
- OCS 42.80
- Support Level
- PDS $44.50
- OCS $18.30
- Resistance Level
- PDS $47.94
- OCS $20.00
- Average True Range (ATR)
- PDS 1.30
- OCS 0.71
- MACD
- PDS 0.65
- OCS 0.09
- Stochastic Oscillator
- PDS 71.58
- OCS 61.35
About PDS Precision Drilling Corporation
Precision Drilling Corpd is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.